ATE442839T1 - Zusammensetzungen und methoden zur behandlung lymphoma - Google Patents

Zusammensetzungen und methoden zur behandlung lymphoma

Info

Publication number
ATE442839T1
ATE442839T1 AT00920004T AT00920004T ATE442839T1 AT E442839 T1 ATE442839 T1 AT E442839T1 AT 00920004 T AT00920004 T AT 00920004T AT 00920004 T AT00920004 T AT 00920004T AT E442839 T1 ATE442839 T1 AT E442839T1
Authority
AT
Austria
Prior art keywords
mol
compositions
methods
cholesterol
lymphoma
Prior art date
Application number
AT00920004T
Other languages
German (de)
English (en)
Inventor
Andreas Sarris
Fernando Cabanillas
Patricia Logan
Clive Burge
James Goldie
Murray Webb
Lawrence D Mayer
Original Assignee
Hana Biosciences Inc
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hana Biosciences Inc, Univ Texas filed Critical Hana Biosciences Inc
Application granted granted Critical
Publication of ATE442839T1 publication Critical patent/ATE442839T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00920004T 1999-04-01 2000-03-31 Zusammensetzungen und methoden zur behandlung lymphoma ATE442839T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12744499P 1999-04-01 1999-04-01
US13719499P 1999-06-02 1999-06-02
PCT/US2000/008669 WO2000059473A1 (en) 1999-04-01 2000-03-31 Compositions and methods for treating lymphoma

Publications (1)

Publication Number Publication Date
ATE442839T1 true ATE442839T1 (de) 2009-10-15

Family

ID=26825635

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00920004T ATE442839T1 (de) 1999-04-01 2000-03-31 Zusammensetzungen und methoden zur behandlung lymphoma

Country Status (13)

Country Link
EP (3) EP1985285A3 (cg-RX-API-DMAC7.html)
JP (3) JP2002541088A (cg-RX-API-DMAC7.html)
AT (1) ATE442839T1 (cg-RX-API-DMAC7.html)
AU (1) AU777572B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0009448B8 (cg-RX-API-DMAC7.html)
CA (1) CA2366787C (cg-RX-API-DMAC7.html)
CY (1) CY1109641T1 (cg-RX-API-DMAC7.html)
DE (1) DE60042968D1 (cg-RX-API-DMAC7.html)
DK (2) DK2266537T3 (cg-RX-API-DMAC7.html)
ES (2) ES2524141T3 (cg-RX-API-DMAC7.html)
IL (4) IL145720A0 (cg-RX-API-DMAC7.html)
PT (1) PT1169021E (cg-RX-API-DMAC7.html)
WO (1) WO2000059473A1 (cg-RX-API-DMAC7.html)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1169021E (pt) * 1999-04-01 2009-11-18 Univ Texas Composições e métodos para o tratamento de linfoma
US6723338B1 (en) 1999-04-01 2004-04-20 Inex Pharmaceuticals Corporation Compositions and methods for treating lymphoma
HK1049787B (en) 1999-10-01 2014-07-25 Immunogen, Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US7303749B1 (en) 1999-10-01 2007-12-04 Immunogen Inc. Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
US7097840B2 (en) 2000-03-16 2006-08-29 Genentech, Inc. Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
ES2332584T3 (es) * 2001-03-27 2010-02-09 Phares Pharmaceutical Research N.V. Metodo y composicion para solubilizar un compuesto biologicamente activo con baja solubilidad en agua.
CA2752140A1 (en) * 2002-05-17 2003-11-27 Celgene Corporation Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-1-yl)-piperidine-2,6-dione for treatment and management of renal cancer
US6890558B2 (en) 2002-05-31 2005-05-10 R.P. Scherer Technologies, Inc. Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
FR2840203B1 (fr) * 2002-05-31 2004-08-27 Scherer Technologies Inc R P Composition pharmaceutique orale pour capsules molles contenant vinorelbine et methode de traitement
US7563810B2 (en) * 2002-11-06 2009-07-21 Celgene Corporation Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
RU2252764C2 (ru) * 2003-03-04 2005-05-27 Российский научный центр рентгенорадиологии МЗ РФ Способ комплексного лечения лимфогранулематоза
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2005011698A1 (en) * 2003-07-28 2005-02-10 Inex Pharmaceuticals Corporation Combination comprising a liposome-encapsulated vinca alkaloid and a topoisomerase ii inhibitor and the use thereof for treating neoplasia
KR101250127B1 (ko) * 2004-07-09 2013-04-02 바이엘 파마 악티엔게젤샤프트 Ｂ-세포 림프종의 치료를 위한 방사성표지된 안티-ｃｄ20항체와의 병용요법
WO2006020618A1 (en) * 2004-08-10 2006-02-23 Inex Pharmaceuticals Corporation Compositions and methods for treating leukemia
CA2736563C (en) 2007-09-10 2016-01-26 Boston Biomedical, Inc. A novel group of stat3 pathway inhibitors and cancer stem cell pathway inhibitors
KR20160125535A (ko) 2008-03-18 2016-10-31 제넨테크, 인크. 항-ｈｅｒ２ 항체-약물 접합체와 화학요법제의 병용물, 및 사용 방법
CA2741265A1 (en) * 2008-10-24 2010-04-29 Gloucester Pharmaceuticals Cancer therapy
MX2015005992A (es) 2012-11-20 2016-03-07 Spectrum Pharmaceuticals Inc Metodo mejorado para la preparacion de la vincristina liposomal encapsulada para el uso terapeutico.
ES2824074T3 (es) * 2013-01-24 2021-05-11 Memorial Sloan Kettering Cancer Center Método para diagnosticar o tratar tumores mediante el uso de liposomas que contienen esfingomielina
KR20150139955A (ko) 2013-04-09 2015-12-14 보스톤 바이오메디칼, 인크. 암 치료에 사용하기 위한 2-아세틸나프토[2,3-b]푸란-4,9-디온
TWI678213B (zh) * 2015-07-22 2019-12-01 美商史倍壯製藥公司 用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
US11299469B2 (en) 2016-11-29 2022-04-12 Sumitomo Dainippon Pharma Oncology, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
SI26542A (sl) 2023-09-12 2025-03-31 Univerza V Ljubljani Nove liposomske formulacije in postopek za njihovo pripravo

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5171578A (en) 1985-06-26 1992-12-15 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US5059421A (en) 1985-07-26 1991-10-22 The Liposome Company, Inc. Preparation of targeted liposome systems of a defined size distribution
US4885172A (en) 1985-06-26 1989-12-05 The Liposome Company, Inc. Composition for targeting, storing and loading of liposomes
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4737323A (en) 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US4952408A (en) * 1988-05-23 1990-08-28 Georgetown University Liposome-encapsulated vinca alkaloids and their use in combatting tumors
US4957773A (en) 1989-02-13 1990-09-18 Syracuse University Deposition of boron-containing films from decaborane
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5165922A (en) * 1990-05-22 1992-11-24 Bristol-Myers Squibb Company Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
GB9304745D0 (en) * 1993-03-09 1993-04-28 Oncholab Ab Use of pharmaceutical formulations
US5595756A (en) * 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5543152A (en) * 1994-06-20 1996-08-06 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5714163A (en) * 1994-06-27 1998-02-03 Nexstar Pharmaceuticals, Inc. Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US5885613A (en) 1994-09-30 1999-03-23 The University Of British Columbia Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5820873A (en) 1994-09-30 1998-10-13 The University Of British Columbia Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5837282A (en) 1996-10-30 1998-11-17 University Of British Columbia Ionophore-mediated liposome loading
US6320017B1 (en) 1997-12-23 2001-11-20 Inex Pharmaceuticals Corp. Polyamide oligomers
PT1169021E (pt) * 1999-04-01 2009-11-18 Univ Texas Composições e métodos para o tratamento de linfoma

Also Published As

Publication number Publication date
JP2002541088A (ja) 2002-12-03
IL212390A (en) 2014-08-31
JP2012158602A (ja) 2012-08-23
AU777572B2 (en) 2004-10-21
ES2333400T3 (es) 2010-02-22
WO2000059473A1 (en) 2000-10-12
BR0009448A (pt) 2002-01-08
EP1985285A3 (en) 2009-08-12
EP1985285A2 (en) 2008-10-29
DK2266537T3 (en) 2014-12-15
DK1169021T3 (da) 2010-01-11
ES2524141T3 (es) 2014-12-04
IL212390A0 (en) 2011-06-30
PT1169021E (pt) 2009-11-18
IL212389A0 (en) 2011-06-30
BRPI0009448B1 (pt) 2018-09-11
EP2266537A2 (en) 2010-12-29
BRPI0009448B8 (pt) 2021-05-25
IL145720A (en) 2011-05-31
IL145720A0 (en) 2002-07-25
DE60042968D1 (de) 2009-10-29
EP2266537A3 (en) 2012-02-22
EP1169021A1 (en) 2002-01-09
CA2366787C (en) 2013-03-12
EP1169021B1 (en) 2009-09-16
CY1109641T1 (el) 2014-08-13
CA2366787A1 (en) 2000-10-12
JP5981214B2 (ja) 2016-08-31
IL212389A (en) 2015-07-30
JP2015071631A (ja) 2015-04-16
AU4060600A (en) 2000-10-23
EP2266537B1 (en) 2014-09-03
HK1152246A1 (en) 2012-02-24

Similar Documents

Publication Publication Date Title
ATE442839T1 (de) Zusammensetzungen und methoden zur behandlung lymphoma
DE69909818D1 (de) Pyrazolopyimidinon-derivate zur behandlung von impotenz
AP1852A (en) '3-Azabicyclo{3.1.0] hexane derivatives as opiate receptors ligands.
ATE284210T1 (de) Verfahren und zusammensetzung zur behandlung von krebs
BRPI9914164B8 (pt) compostos de 3-ciano quinolina
ATE295347T1 (de) Stoffe und zusammensetzungen für die verabreichung aktiver substanzen
MY120038A (en) Method and composition for inhibiting growth of microorganisms including peracetic acid and a non- oxidizing biocide.
DK1200418T3 (da) Nematodicide trifluorbutener
CA2334907A1 (en) Method and composition for inhibiting growth of microorganisms including peracetic acid and a non-oxidizing biocide
GB0011203D0 (en) Chemical compounds
SE0104248D0 (sv) Method of treatment
PL338181A1 (en) Novel chemical compounds
IL115920A0 (en) 2,2-dichloroalkanecarboxylic acids process of their production and pharmaceutical agents containing these
WO2004033423A3 (en) Anticancer compounds
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
MXPA03012039A (es) Derivados de benzo [g]quinolina para tratar glaucoma y miopia.
AP2000001937A0 (en) Method for identifying chemical active agents and active agents for inhibiting the 1-desoxy-d-xylulose-5-phosphate biosynthetic pathway.
DE60224884D1 (de) Verfahren zur herstellung von 3, 3', 6, 6'-tetraalkylen-2, 2'-biphenolen und 3, 3', 6, 6'-tetraalkylen-5, 5'-dihalo-2, 2' biphenolen
ATE393624T1 (de) Verwendung von sesquiterpene enthaltenden zusammenstellungen zur behandlung von krebs
ATE299851T1 (de) Verfahren zur herstellung von zwischenprodukten
MXPA03010737A (es) Aril-8-azabiciclo(3.2.1) octanos para tratamiento de depresion.
BR0008791A (pt) Derivados anticonvulsivos, úteis no tratamento de tremor essencial
EA200001157A2 (ru) Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции
ATE233759T1 (de) Verfahren zur herstellung vom (r)-(+)-3- 1-(2-(4- benzoyl-2-(3,4-difluorophenyl)morpholin-2- yl)ethyl)-4-phenylpiperidin-4-yl -1,1- dimethylharnstoff, deren salzen, solvaten und/oder hydraten
MY130771A (en) 3-azabicyclo [3.1.0] hexane derivatives useful in therapy.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1169021

Country of ref document: EP